← Back to all trials
Not Yet Recruiting
NCT05681715
A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
Conditions: Generalized Myasthenia Gravis
Sex: All
Ages: 18 Years – N/A
Phase: PHASE3
Enrollment: 30
Sponsor: UCB Biopharma SRL
Summary
The purpose of this study is to evaluate the ability of study participants with generalized Myasthenia Gravis (gMG) to successfully self-administer rozanolixizumab after training in the self-administration technique using the syringe driver and manual push methods.
Eligibility Criteria
Inclusion Criteria:Study participant must have a documented diagnosis of generalized Myasthenia Gravis (gMG)Study participant is willing to perform and capable of performing home self-administrationStudy participant is considered by the investigator for additional rozanolixizumab treatment with the posology proposed in this study.Body weight ≥35 kgStudy participants may be male or femaleExclusion Criteria:Study participant has a known hypersensitivity to any components of the study medication or other anti-neonatal Fc receptor (FcRn) medicationsStudy participant with a known tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent tuberculosis infection (LTBI), or current or history of nontuberculous mycobacterial infection (NTMBI)Study participant has a clinically relevant active infection or a history of serious infection (resulting in hospitalization or requiring IV antibiotic treatment) within 6 weeks before the Baseline VisitThe study participant previously participated in any rozanolixizumab MG study and met any mandatory withdrawal or mandatory study drug discontinuation criteriaStudy participant has received a live vaccination within 4 weeks before starting treatment, or a Bacillus Calmette-Guérin (BCG) vaccine within 1 year before starting treatment; or intends to have a live vaccination during the course of the study or within 8 weeks following the last dose of rozanolixizumabStudy participant with severe (defined as Grade 3 on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale) weakness affecting oropharyngeal or respiratory muscles, or who has myasthenic crisis or impending crisis
Source: ClinicalTrials.gov (NCT05681715). StuddyBuddy aggregates publicly available trial information.